Presentation on Thursday, February 2nd, 2023 at 10:00 AM ET
SAN
DIEGO, Jan. 31, 2023 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a company developing medical
technology to treat cancer and life-threatening infectious
disease, announced today that it will be presenting
virtually at the upcoming Sequire Biotechnology Conference on
Thursday, February 2nd, at
10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and
Chief Scientific Officer of Aethlon Medical, will be giving the
presentation.
Event: Aethlon Medical, Inc. Presentation at the
Sequire Biotechnology Conference
Date: Thursday, February 2nd, 2023
Time: 10:00 am ET
Register to watch the presentation HERE.
Summary of Sequire Biotechnology Conference
Expected to reach over $727
billion by 2025, the Biotechnology industry is showing
consistent growth with over 6,500 biotech companies within the US
and over 20,000 worldwide This one-day virtual investor event,
highlighting public companies in the biotechnology space, will be
held via SRAX's Sequire Virtual Events platform. Thousands of
active biotechnology investors have been invited to the event,
which will feature several biotechnology focused companies hosting
25 minute presentations, alongside keynotes highlighting prominent
names in this space.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on
developing the Hemopurifier, a clinical stage immunotherapeutic
device designed to combat cancer and life-threatening viral
infections, as its lead technology. In human studies, the
Hemopurifier has demonstrated the removal of life-threatening
viruses and harmful exosomes from blood utilizing a proprietary
lectin-based technology. This action has potential
applications in cancer, where exosomes may promote immune
suppression and metastasis, and in life-threatening infectious
diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA)
designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease.
The Hemopurifier also holds an FDA Breakthrough Device
designation and an open IDE application related to the treatment of
life-threatening viruses that are not addressed with approved
therapies.
Additional information can be found at
www.AethlonMedical.com.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-sequire-biotechnology-conference-on-february-2nd-2023-301734390.html
SOURCE Aethlon Medical, Inc.